Sepsis, Management & Advances in Metabolomics.

Area of Science:

• Biochemistry
• Clinical Medicine
• Medical Diagnostics

Background:

• Early and accurate diagnosis and risk stratification of septic shock patients remain significant clinical challenges.
• Septic shock is multifactorial, with variable symptoms and patient-specific comorbidities complicating early assessment.
• Current treatment strategies are often not personalized, relying on traditional progression-based approaches.

Purpose of the Study:

• To highlight the limitations of current diagnostic and prognostic biomarkers for septic shock.
• To emphasize the need for sensitive and specific biomarkers for early diagnosis, prognosis, and drug development.
• To propose the integration of clinical data with metabolomics for improved patient management.

Main Methods:

• Review of existing literature on septic shock biomarkers and diagnostic challenges.
• Discussion on the limitations of traditional biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), and cytokines.
• Exploration of the potential of metabolomics in conjunction with clinical data.

Main Results:

• Traditional biomarkers lack the required sensitivity and specificity for reliable septic shock diagnosis and prognosis.
• A single biomarker is insufficient to fully characterize septic shock patients.
• Metabolomics offers a comprehensive analytical approach to understand disease complexity.

Conclusions:

• Integrating clinical data with metabolomics can enhance the understanding of septic shock pathophysiology.
• This integrated approach can facilitate better patient stratification and prediction of clinical outcomes.
• The development of novel, sensitive, and specific biomarkers is crucial for advancing septic shock care.